Biosimilars approved in Paraguay

Biosimilars/General | Posted 15/10/2021 post-comment0 Post your comment

In Paraguay, the regulatory body responsible for the approval of biological drugs is the National Directorate for Sanitary Surveillance (Dirección Nacional de Vigilancia Sanitaria, DINAVISA).


The mission of DINAVISA is to guarantee the fulfillment of the functions of stewardship, management, financing and provision of health services, with the aim to reach universal coverage, under the approach of social protection, within the framework of the National System of Health.

On 29 December 2016, the legal framework for the requirements and guidelines for the Sanitary Registry of biosimilar medicines by comparability was stablished through Chapter IV of the Decree 6611 by which Article 24 of Law N 1119/1997 is regulated, ‘On health products and others’, and the requirements for the registration of biological medicines are established.

DINAVISA defines similar biological medicine or biosimilar as a biological medicine that demonstrate similarity in terms of safety, quality, efficacy and immunogenicity to the reference biological medicine through the established comparability exercise.

To date, DINAVISA has approved two monoclonal biosimilar antibodies [1] for use in Paraguay, see Table 1. 

Table 1: Biosimilars approved by DINAVISA
Product name Active substance Therapeutic area Manufacturer/
Company name
Bevacizumab Bioethics bevacizumab Breast cancer
Colon cancer
Rituximab Bioethics rituximab Rheumatoid arthritis
Non-Hodgkin's lymphoma
Data updated on 15 October 2021.


Two biomimics of rituximab for the treatment of rheumatoid arthritis, leukemia and non-Hodgkin lymphoma are also approved in Paraguay:
1. Novex (Tasiur)
2. Reditux/Tidecron

Biomimics are intended copies, unregulated biologicals, biocopies, which cannot be considered biosimilars unless they have been reviewed and approved by the appropriate regulatory agencies in accordance with the international guidelines provided by the World Health Organization (WHO) for the approval of biosimilars [2].

Editor's comments
European Medicines Agency regulatory requirements ensure the same high standards of quality, safety, and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product but they are not universally accepted by regulatory bodies outside of the European Union (EU). It should be noted that ‘biosimilars’ approved in Paraguay might not have been authorized if they had been subjected to the strict regulatory processes required for approval of biosimilars in the EU.

Related articles
The biosimilars market in Latin America: a summary

Similar biotherapeutic products approved and marketed in Latin America


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Posible colaboración biotecnológica entre India y Colombia

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Posible colaboración biotecnológica entre India y Colombia

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. Ortiz-Prado E, Ponce-Zea J, Vasconez JE, Castillo D, Checa-Jaramillo DC, Rodrí¬guez-Burneo N, Andrade F, Intriago-Baldeón DP, Galarza-Maldonado C. Current trends for biosimilars in the Latin American market. Generics Biosimilars Initiative Journal. (GaBI Journal). 2020;9(2):64-74. doi:10.5639/gabij.2020.0902.011
2. GaBI Online - Generics and Biosimilars Initiative. Glosario de términos principales []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 15]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.


comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010